Maternal and infant HIV research
PREGART
Comparing dolutegravir and low-dose efavirenz during pregnancy and breastfeeding, with follow-up of mothers and their children.
Study overview
Evidence for mothers and babies
PREGART is a multicentre, randomised Phase 4 non-inferiority trial in Ethiopia and Uganda. It compares dolutegravir-based and EFV400-based antiretroviral regimens in women living with HIV. Mildmay Hospital Uganda is listed among the Ugandan study sites.
Research questions
Three primary areas of assessment
Maternal viral suppression
Compare viral suppression at delivery between the treatment groups.
Infant HIV prevention
Compare mother-to-child transmission outcomes through the infant's first year.
Pregnancy and neonatal safety
Compare adverse pregnancy, maternal and neonatal outcomes.
The continuing programme
PREGART 2
The consortium launched PREGART 2 in Kampala in February 2026. Karolinska Institutet coordinates the programme under Prof. Eleni Aklillu, with partners in Uganda, Ethiopia, Sweden and Italy.
The launch included a visit to Mildmay Hospital and highlighted investment in laboratory and research capacity.
Read the consortium's launch updateCollaboration and support
The consortium includes Karolinska Institutet, Hawassa University, Makerere University and Istituto Superiore di Sanità. The programme began with EDCTP2 support and continues with Global Health EDCTP3 funding.
Use the official project website for consortium contacts and the latest study updates.
Official PREGART website